Beyond their metabolic effects, DPP-4 is also highly expressed on endothelial and epithelial cells in lung tissues, prompting interest in the use of DPP-4 inhibitors in various pulmonary conditions, including pulmonary fibrosis, asthma, acute lung injury, and even COVID-19 13,14. This evidence concerns the gene DPP4 and COVID-19.